What it's for (Indications)
- Empagliflozin is a highly effective medication indicated for various significant clinical conditions, primarily focusing on metabolic, cardiovascular, and renal health.
- For adults with type 2 diabetes mellitus, it is prescribed to improve glycemic control by reducing elevated blood glucose levels, often used as an adjunct to diet and exercise.
- Beyond glycemic management, empagliflozin holds crucial indications for cardiovascular protection; specifically, it is approved to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
- Furthermore, its utility extends to heart failure, where it is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (encompassing both heart failure with reduced ejection fraction [HFrEF] and heart failure with preserved ejection fraction [HFpEF]).
- Most recently, empagliflozin has gained approval for chronic kidney disease (CKD), indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with CKD.
- This broad range of indications underscores its multifaceted benefits in complex patient populations.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosing regimen for empagliflozin varies slightly depending on the specific indication and patient's renal function, emphasizing individualized care. For adults with type 2 diabetes mellitus, the usual starting dose is 10 mg orally once daily, taken in the morning with or without food. If additional glycemic control is required and the patient tolerates the initial dose, the dosage may be increased to a maximum of 25 mg once daily. For the reduction of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease, the recommended dose is 10 mg once daily. Similarly, for the treatment of heart failure (HFrEF or HFpEF) and for chronic kidney disease, the recommended dose is 10 mg orally once daily. It is imperative to assess renal function (eGFR) prior to initiation and periodically thereafter. Empagliflozin initiation is not recommended in patients with an eGFR less than 20 mL/min/1.73 m² for the treatment of CKD or HF, and generally not recommended below 30 mL/min/1.73 m² for glycemic control. Dosage adjustments are not typically required for hepatic impairment. |
Safety & Warnings
Common Side Effects
- Empagliflozin is generally well-tolerated, but like all medications, it is associated with a range of potential side effects, some of which can be serious.
- Common side effects include urinary tract infections (UTIs), genital mycotic infections (e.
- g.
- , vulvovaginal candidiasis, balanitis), increased urination (polyuria), thirst, and nausea.
- Due to its mechanism of action, which involves increased urinary glucose excretion, these genitourinary infections are more frequently observed.
- More serious adverse events, though less common, warrant careful monitoring.
- These include diabetic ketoacidosis, which can occur even with blood glucose levels that are not severely elevated, requiring prompt medical attention.
- Acute kidney injury and impairment of renal function have been reported, necessitating vigilance, especially in patients with pre-existing renal impairment or those on other nephrotoxic medications.
- Hypotension and volume depletion may occur, particularly in elderly patients, those with impaired renal function, or those concurrently taking diuretics.
- Rare but severe adverse events include Fournier's gangrene (necrotizing fasciitis of the perineum), a serious bacterial infection that requires urgent surgical intervention.
- Hypersensitivity reactions, such as urticaria and angioedema, are also possible.
Serious Warnings
- Black Box Warning: Empagliflozin (Jardiance) does **not** carry a specific FDA-mandated Black Box Warning at this time. However, due to the potential for serious adverse events, clinicians and patients must be fully aware of critical safety information, which is often highlighted in a "Serious Warnings" section within prescribing information. Patients and healthcare providers should be particularly vigilant for the development of diabetic ketoacidosis (DKA), which can occur even in patients with only moderately elevated blood glucose levels (euglycemic DKA) and may require immediate hospitalization. The risk of urosepsis and pyelonephritis, originating from urinary tract infections, is also a serious concern that demands prompt medical evaluation and treatment. Furthermore, a rare but severe and rapidly progressing bacterial infection, Fournier's gangrene (necrotizing fasciitis of the perineum), has been reported with SGLT2 inhibitors, necessitating urgent surgical intervention if suspected. Volume depletion and hypotension are potential risks, especially in vulnerable populations such as the elderly, those with renal impairment, or patients on diuretics. Renal function should be monitored closely, as acute kidney injury has been observed. Despite the absence of a formal Black Box Warning, these serious safety considerations underscore the importance of careful patient selection, education, and ongoing monitoring during empagliflozin therapy.
- Empagliflozin therapy necessitates careful consideration of several important warnings to ensure patient safety and optimize treatment outcomes.
- A significant concern is the risk of diabetic ketoacidosis (DKA), which can occur in patients with type 1 or type 2 diabetes, sometimes with only moderately elevated blood glucose levels (euglycemic DKA).
- Patients should be educated on the symptoms of DKA (nausea, vomiting, abdominal pain, excessive thirst, rapid breathing, unusual fatigue) and advised to seek immediate medical attention if these occur.
- Volume depletion and hypotension, particularly in elderly patients, those with renal impairment, or individuals concurrently receiving diuretics, represent another critical warning; hydration status and blood pressure should be monitored.
- There is an increased risk of urosepsis and pyelonephritis stemming from urinary tract infections, which can become serious.
- A rare but life-threatening warning is Fournier's gangrene (necrotizing fasciitis of the perineum), a severe, rapidly progressing infection that requires urgent surgical debridement.
- The risk of genital mycotic infections is also elevated.
- Empagliflozin can cause acute kidney injury, and renal function should be assessed before initiation and periodically during treatment.
- When used in combination with insulin or sulfonylureas, the risk of hypoglycemia is increased, and dosage adjustments of these concomitant medications may be necessary.
How it Works (Mechanism of Action)
Empagliflozin exerts its therapeutic effects primarily by selectively and reversibly inhibiting the sodium-glucose co-transporter 2 (SGLT2), located in the S1 segment of the renal proximal tubule. Under normal physiological conditions, SGLT2 is responsible for reabsorbing approximately 90% of the filtered glucose from the tubular lumen back into the systemic circulation. By inhibiting SGLT2, empagliflozin significantly reduces the reabsorption of glucose, leading to increased urinary glucose excretion (glucosuria), thereby lowering plasma glucose concentrations in an insulin-independent manner. This mechanism contributes to improved glycemic control in patients with type 2 diabetes. Beyond glucose lowering, the SGLT2 inhibition also induces an osmotic diuresis and natriuresis, promoting a mild diuretic effect, reduction in blood pressure, and modest weight loss. These effects are believed to contribute to the observed cardiovascular and renal benefits, including a reduction in cardiac preload and afterload, improved myocardial energetics, and a decrease in intraglomerular pressure, which mitigates hyperfiltration and protects renal function. The precise interplay of these mechanisms underlies empagliflozin's broad beneficial profile in metabolic, cardiovascular, and renal disease.